Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:ALBO
- CUSIP: N/A
- Web: www.albireopharma.com
Capitalization:- Market Cap: $197.54 million
- Outstanding Shares: 8,882,000
Average Prices:- 50 Day Moving Avg: $23.53
- 200 Day Moving Avg: $22.43
- 52 Week Range: $12.00 - $37.69
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.47
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.27 million
- Price / Sales: 60.41
- Book Value: $8.49 per share
- Price / Book: 2.62
Profitability:Debt:- Current Ratio: 8.64%
- Quick Ratio: 8.64%
Misc:- Average Volume: 24,944 shs.
- Beta: 1.45
- Short Ratio: 1.32
Frequently Asked Questions for Biodel (NASDAQ:ALBO)
What is Biodel's stock symbol?
Biodel trades on the NASDAQ under the ticker symbol "ALBO."
How were Biodel's earnings last quarter?
Biodel Inc. (NASDAQ:ALBO) posted its earnings results on Monday, August, 21st. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.02. View Biodel's Earnings History.
Where is Biodel's stock going? Where will Biodel's stock price be in 2017?
5 brokers have issued twelve-month target prices for Biodel's shares. Their forecasts range from $35.00 to $58.00. On average, they anticipate Biodel's stock price to reach $46.50 in the next year. View Analyst Ratings for Biodel.
Who are some of Biodel's key competitors?
Some companies that are related to Biodel include NanoString Technologies (NSTG), Surmodics (SRDX), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), Addus HomeCare Corporation (ADUS), Corium International (CORI), Flamel Technologies S.A. (AVDL), Computer Programs and Systems (CPSI), Rockwell Medical (RMTI), Bellicum Pharmaceuticals (BLCM), Pharming Group (PHGUF), Accuray Incorporated (ARAY), Depomed (DEPO), Oxford Immunotec Global PLC (OXFD), Teligent (TLGT), Capital Senior Living Corporation (CSU), Arbutus Biopharma Corporation (ABUS) and Zogenix (ZGNX).
How do I buy Biodel stock?
Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biodel's stock price today?
One share of Biodel stock can currently be purchased for approximately $22.24.
MarketBeat Community Rating for Biodel (NASDAQ ALBO)MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Biodel (NASDAQ:ALBO)Earnings History by Quarter for Biodel (NASDAQ ALBO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/21/2017 | 6/30/2017 | ($0.84) | ($0.86) | | | View | N/A |  |
| 5/10/2017 | Q2 2017 | ($1.11) | ($1.06) | | | View | N/A | |
| 8/11/2016 | Q216 | | ($0.05) | | | View | N/A | |
| 5/9/2016 | Q2 | ($0.04) | ($0.09) | | | View | N/A | |
| 2/16/2016 | Q1 | ($0.08) | ($0.05) | | | View | N/A | |
| 12/17/2015 | Q315 | ($0.11) | ($0.05) | | | View | Listen | |
| 8/13/2015 | Q3 | ($0.10) | ($0.12) | | | View | Listen | |
| 5/6/2015 | Q215 | ($0.23) | ($0.27) | | | View | N/A | |
| 2/12/2015 | Q115 | ($0.18) | ($0.20) | | | View | N/A | |
| 12/17/2014 | Q414 | ($0.27) | ($0.16) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.26) | ($0.15) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.26) | ($0.29) | | | View | N/A | |
| 2/6/2014 | Q4 | ($0.19) | ($0.20) | | | View | N/A | |
| 12/18/2013 | Q4 | ($0.30) | ($0.04) | | | View | Listen | |
| 8/12/2013 | Q3 2013 | ($0.37) | ($0.66) | | | View | N/A | |
| 5/8/2013 | Q2 2013 | ($0.43) | ($0.37) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biodel (NASDAQ:ALBO)2017 EPS Consensus Estimate: ($3.37)
2018 EPS Consensus Estimate: ($3.06)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.91) | ($0.91) | ($0.91) |
| Q2 2017 | 1 | ($0.87) | ($0.87) | ($0.87) |
| Q3 2017 | 2 | ($0.79) | ($0.76) | ($0.78) |
| Q4 2017 | 2 | ($0.86) | ($0.77) | ($0.82) |
| Q1 2018 | 1 | ($0.76) | ($0.76) | ($0.76) |
| Q2 2018 | 1 | ($0.76) | ($0.76) | ($0.76) |
| Q3 2018 | 1 | ($0.77) | ($0.77) | ($0.77) |
| Q4 2018 | 1 | ($0.77) | ($0.77) | ($0.77) |
(Data provided by Zacks Investment Research)
Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 27.36%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/20/2013 | Brian Jg Pereira | Director | Sell | 4,734 | $2.26 | $10,698.84 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
| Source: |
|
| Date | Headline |
|---|
 | Albireo to Present at Investor Conferences in September
finance.yahoo.com - September 19 at 3:44 PM |
 | -$0.85 EPS Expected for Biodel Inc. (ALBO) This Quarter
www.americanbankingnews.com - September 19 at 2:18 AM |
 | Albireo Pharma (ALBO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 4:14 PM |
| Biodel Inc. (ALBO) to Post Q3 2017 Earnings of ($0.76) Per Share, Wedbush Forecasts
www.americanbankingnews.com - September 14 at 7:27 AM |
| Biodel Inc. (ALBO) to Post FY2020 Earnings of ($3.25) Per Share, Wedbush Forecasts
www.americanbankingnews.com - September 13 at 4:02 PM |
| Biodel Inc. (ALBO) Rating Reiterated by Wedbush
www.americanbankingnews.com - September 11 at 9:32 PM |
| Biodel Inc. (ALBO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 10 at 2:42 AM |
| Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 5:09 PM |
| Q3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair
www.americanbankingnews.com - August 23 at 8:22 AM |
| Biodel Inc. (ALBO) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 22 at 10:31 AM |
| Albireo Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 21 at 3:51 PM |
| Biodel Inc. (ALBO) Coverage Initiated by Analysts at Cowen and Company
www.americanbankingnews.com - August 20 at 11:58 PM |
| Biodel Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 16 at 10:54 AM |
| Brokerages Anticipate Biodel Inc. (ALBO) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - August 13 at 4:16 AM |
| Albireo to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 3:38 PM |
| Biodel Inc. (ALBO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 1 at 7:46 PM |
 | What's in the Cards for Humana (HUM) this Earnings Season?
www.nasdaq.com - July 31 at 3:50 PM |
| What's in the Cards for Merrimack (MACK) in Q2 Earnings?
www.nasdaq.com - July 28 at 4:19 PM |
| Endo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial Review
www.americanbankingnews.com - July 16 at 2:11 PM |
| Biodel Inc. (ALBO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM |
| Comparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - July 7 at 8:28 PM |
| Zacks: Biodel Inc. (ALBO) Given $49.00 Average Price Target by Brokerages
www.americanbankingnews.com - July 6 at 10:37 PM |
| Biodel (ALBO) & Endo International PLC (ENDP) Financial Comparison
www.americanbankingnews.com - July 6 at 12:32 AM |
| Research Analysts Set Expectations for Biodel Inc.'s FY2017 Earnings (NASDAQ:ALBO)
www.americanbankingnews.com - July 3 at 8:34 AM |
| Biodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - July 1 at 12:02 PM |
| Brokerages Anticipate Biodel Inc. (ALBO) Will Announce Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 29 at 6:26 PM |
| Analyzing Biodel (ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - June 27 at 12:40 AM |
| Analysts Anticipate Biodel Inc. (ALBO) to Post ($0.87) EPS
www.americanbankingnews.com - June 21 at 6:32 PM |
| Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 5 at 4:06 PM |
| Albireo Pharma, Inc. (ALBO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 2 at 7:30 PM |
| Company Spotlight: Albireo Pharma - Nasdaq.com - Nasdaq
www.nasdaq.com - June 2 at 4:33 PM |
| Q2 2017 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair
www.americanbankingnews.com - June 2 at 7:18 AM |
 | Company Spotlight: Albireo Pharma
www.rttnews.com - June 2 at 1:46 AM |
| ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD - Nasdaq
www.nasdaq.com - May 31 at 3:26 PM |
 | Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com - May 31 at 11:06 AM |
| Zacks: Albireo Pharma, Inc. (ALBO) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 31 at 8:34 AM |
| Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase ... - GlobeNewswire (press release)
globenewswire.com - May 30 at 8:36 PM |
| Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 30 at 8:36 PM |
| BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Atwood Oceanics, Xactly, Protagonist Therapeutics ... - Nasdaq
www.nasdaq.com - May 30 at 3:35 PM |
 | Albireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share - StreetInsider.com
www.streetinsider.com - May 25 at 1:36 AM |
| Albireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share
www.streetinsider.com - May 24 at 3:26 PM |
| Albireo Prices $45.1 Million Public Offering of Common Stock
finance.yahoo.com - May 24 at 3:26 PM |
| Albireo Pharma (ALBO) Commences Offering of Common Stock - StreetInsider.com
www.streetinsider.com - May 24 at 7:23 AM |
| Albireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 24 at 7:23 AM |
| Albireo Pharma, Inc. (ALBO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 23 at 7:28 PM |
| Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
finance.yahoo.com - May 18 at 12:18 PM |
| Albireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for A4250 with Term into 2031
www.streetinsider.com - May 16 at 8:33 PM |
| Albireo Pharma, Inc. (ALBO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 8:18 PM |
| Albireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for ... - StreetInsider.com
www.streetinsider.com - May 16 at 3:31 PM |
| Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
finance.yahoo.com - May 16 at 3:31 PM |
Biodel (ALBO) Chart for Friday, September, 22, 2017
